Featured Research

from universities, journals, and other organizations

New Therapeutic Approach To Combat Lymphoma

Date:
March 19, 2009
Source:
ETH Zurich
Summary:
Using the human antibody, L19, which they developed themselves and specifically recognizes the blood vessels in tumor tissue, researchers have succeeded in eliminating lymphatic tumors in both mice and humans. For their study, they combined L19 with known anticancer substances.

Regression of a Hodgkin lymphoma after treatment with the new cancer drug L19-131I. On the left, you can see several metastases in a young patient thanks to a so-called FDG-PET scan (black spots; the coloring of the brain, heart and bladder is methodical). On the right, all the lesions disappeared six weeks after treatment with L19-131I.
Credit: G. Mariani and P. Erba, University of Pisa

Using the human antibody, L19, which they developed themselves and specifically recognizes the blood vessels in tumor tissue, researchers at ETH Zurich have succeeded in eliminating lymphatic tumors in both mice and humans. For their study, they combined L19 with known anticancer substances.

The fastest growing sector in pharmaceutical biotechnology is monoclonal antibodies. Their products are used especially in cancer therapy. There is a good reason for this: Monoclonal antibodies specifically recognize molecular targets, including those typical for cancer.

Most antibody-based cancer medications on the market, such as herceptin, avastin or erbitux for instance, cannot cure the disease. The monoclonal “rituximab”, however, which generated over four billion dollars in 2008 for Roche/Genentech, produces impressive therapeutic results. Combined with CHOP – a form of chemotherapy – it increased the 5-year life expectancy of patients suffering from a certain type of non-Hodgkin lymphoma by 15%.

Finding the tumor blood vessels with L19

One avenue towards the development of more selective anti-cancer drugs consists in the targeted delivery of bioactive molecules (e.g., drugs, cytokines,radionuclides) to the tumor environment by means of monoclonal antibodies specific to tumor-associated markers. In this context, the targeted delivery of therapeutic agents to newly-formed blood vessels (“vascular targeting”) is particularly attractive, because of the dependence of tumors on new blood vessels to sustain growth and invasion, and because of the accessibility of neo-vascular structures for therapeutic agents injected intravenously.

The team headed by ETH Zurich professor Dario Neri from the Institute of Pharmaceutical Science has developed a number of these antibodies over the last decade. In the last issue of the journal Blood, the ETH Zurich researchers describe how they managed to completely eliminate certain lymphatic tumors in both mice and humans.

The Neri team used their own antibody, L19, for their research. Three cancer drugs based on the L19 antibody are currently in phases 1 and 2 of various clinical trials in association with the companies Bayer Schering Pharma and Philogen, which Dario Neri co-founded. L19-based therapeutic approaches have already produced some exceptional results: When patients with Hodgkin’s lymphoma were treated with radioimmunotherapy (i.e., by administration of the monoclonal antibody L19 coupled to the radionuclide 131I), there was a noticeable decrease in cancer lesions (see photo).

New improved rituximab

Not only did the ETH Zurich researchers succeed in finding therapies for humans in their studies; in a second article they also showed how the substance L19-IL2 dramatically improves the effect of the aforementioned cancer substance rituximab in mice, leading to the complete elimination of non-Hodgkin lymphoma. Up to now, rituximab is typically used in combination with chemotherapy (e.g., with the CHOP regimen).

The success of the Neri team’s new therapeutic approach relies on the ability of the immunocytokine L19-IL2 to attract and activate certain white blood cells, including the so-called natural killer cells, towards the tumor, thus potentiating the therapeutic activity of rituximab. The fact that the treated mice did not lose weight suggests that the new combination treatment modality may be well tolerated, thus providing a rationale for the clinical testing of L19-IL2 in combination with rituxan or other antibodies.


Story Source:

The above story is based on materials provided by ETH Zurich. Note: Materials may be edited for content and length.


Journal References:

  1. Sauer et al. Expression of the oncofetal ED-B–containing fibronectin isoform in hematologic tumors enables ED-B–targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood, DOI: 10.1182/blood-2008-06-160416
  2. Schliemann et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood, 2009; 113 (10): 2275 DOI: 10.1182/blood-2008-05-160747

Cite This Page:

ETH Zurich. "New Therapeutic Approach To Combat Lymphoma." ScienceDaily. ScienceDaily, 19 March 2009. <www.sciencedaily.com/releases/2009/03/090312214725.htm>.
ETH Zurich. (2009, March 19). New Therapeutic Approach To Combat Lymphoma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/03/090312214725.htm
ETH Zurich. "New Therapeutic Approach To Combat Lymphoma." ScienceDaily. www.sciencedaily.com/releases/2009/03/090312214725.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins